Product Information
MEFLOQUINE HCL 250 MG TABLET is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $3.9742 per EA under NDC 00555017178. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Dec 29, 2003. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
250 mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00555017178
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
MEFLOQUINE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA076392FDA Approved
12/29/2003
TE Code
AB
On Market Since
1/6/2004
Pharmacological Classes
Price Statistics
The NADAC for MEFLOQUINE HCL 250 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 18.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $3.9742 per EA |
|---|---|
| All-time high | $6.3637 (Sep 10, 2014) |
| All-time low | $2.8103 (Aug 23, 2023) |
| 52-week high | $5.0310 |
| 52-week low | $3.9742 |
| Median price | $4.0745 |
| Average price | $4.2114 |
| Largest weekly change | +52.2% (Aug 20, 2025) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Mefloquine Hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Antimalarial class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of MEFLOQUINE HCL 250 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for MEFLOQUINE HCL 250 MG TABLET, manufactured by Teva Pharmaceuticals USA Inc., is $3.9742 per EA (NDC 00555017178), effective Sep 30, 2026.
How has the price of MEFLOQUINE HCL 250 MG TABLET changed over time?
Over the history we have for it, the NADAC for MEFLOQUINE HCL 250 MG TABLET has declined 18.5%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for MEFLOQUINE HCL 250 MG TABLET?
Since Nov 28, 2013, the NADAC for MEFLOQUINE HCL 250 MG TABLET has ranged from a low of $2.8103 (Aug 23, 2023) to a high of $6.3637 (Sep 10, 2014), with a median of $4.0745 per EA.
Are there cheaper alternatives to MEFLOQUINE HCL 250 MG TABLET?
1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength as MEFLOQUINE HCL 250 MG TABLET in a comparable dosage form, but none are currently priced below it.
Who manufactures MEFLOQUINE HCL 250 MG TABLET?
MEFLOQUINE HCL 250 MG TABLET (NDC 00555017178) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.